Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-12-10 pm EST 		5-day change 1st Jan Change
58.12 USD -1.00% Intraday chart for Bristol-Myers Squibb Company -0.97% +13.27%
Dec. 10 Agilent Cancer Diagnostic Assay Receives Certification to Comply with New EU Regulations MT
Dec. 10 Berenberg Raises Price Target on Bristol-Myers Squibb to $60 From $55, Keeps Hold Rating MT
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In

Latest news about Bristol-Myers Squibb Company

Agilent Cancer Diagnostic Assay Receives Certification to Comply with New EU Regulations Dec. 10 MT
Berenberg Raises Price Target on Bristol-Myers Squibb to $60 From $55, Keeps Hold Rating Dec. 10 MT
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio At Ash 2024 with Long-Term Survival Data and Results from Expanding Pipeline Dec. 09 CI
Nuvig Therapeutics, Inc. announced that it has received $161 million in funding from a group of investors Dec. 04 CI
Bristol-Myers Seeks Bolt-On Acquisitions Dec. 03 CI
Bristol-Myers Squibb Company Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 08:00 AM Dec. 03
AI Proteins, Inc. Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued Up to $400 Million Dec. 03 CI
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List Nov. 29 MT
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating Nov. 25 MT
Wall Street warms to AI's glow Nov. 22Our Logo
Bristol Myers: presents new data to ASH Nov. 19 CF
Bristol Myers Squibb?s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms Nov. 19 CI
Bristol-Myers Squibb Company Presents at Jefferies London Healthcare Conference 2024, Nov-19-2024 09:30 AM Nov. 19
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $60 From $52, Maintains Equalweight Nov. 18 MT
HSBC Adjusts Bristol-Myers Squibb Price Target to $58 From $50, Maintains Hold Rating Nov. 15 MT
Bristol-Myers Says European Committee Recommends Approval of Opdivo-Yervoy Combination Therapy for Colorectal Cancer Nov. 15 MT
Bristol Myers Squibb's Augtyro Recommended for EU Approval Nov. 15 MT
Bristol Myers: positive opinion from CHMP for Opdivo Nov. 15 CF
Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug Nov. 15 DJ
Bristol-Myers Says European Committee Recommends Approval of Repotrectinib Nov. 15 MT
Bristol Myers: positive opinion for repotrectinib in U Nov. 15 CF
Bristol-Myers Squibb Faces $6.7 Billion Lawsuit in Renewed Cancer Drug Delay Case Nov. 15 MT
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors Nov. 15 CI
JPMorgan Adjusts Price Target on Bristol-Myers Squibb to $70 From $64, Keeps Overweight Rating Nov. 13 MT
Analyst recommendations: Spotify, Starbucks, Tesla, Block, Coinbase... Nov. 13Our Logo

Chart Bristol-Myers Squibb Company

Chart Bristol-Myers Squibb Company
BMY: Dynamic Chart

Company Profile

Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Employees
34,100
Sector
Pharmaceuticals
Calendar
2025-02-06 - Q4 2024 Earnings Release
More about the company

Income Statement and Estimates

income-statement-evolution-chart BRISTOL-MYERS-SQUIBB-COMP More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
B
surperformance-ratings-light-chart BRISTOL-MYERS-SQUIBB-COMPMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
58.12USD
Average target price
60.46USD
Spread / Average Target
+4.02%
Consensus
Profit revisions
estimates-change-chart BRISTOL-MYERS-SQUIBB-COMP Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart BRISTOL-MYERS-SQUIBB-COMP Company calendar
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. News Bristol-Myers Squibb Company
  5. Jefferies Trims Bristol-Myers Squibb's Price Target to $61 From $62, Hold Rating Maintained